• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿德福韦酯及中药联合阿德福韦酯治疗慢性乙型肝炎完全应答和无应答患者的动态建模与模拟。

Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy.

机构信息

School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China ; School of Automation and Electrical Engineering, University of Science and Technology Beijing, Beijing 100083, China.

出版信息

Evid Based Complement Alternat Med. 2013;2013:767290. doi: 10.1155/2013/767290. Epub 2013 Nov 6.

DOI:10.1155/2013/767290
PMID:24282437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3825269/
Abstract

ChiCTR-TRC-11001263 study was the first large-scale double-blind randomized placebo-controlled traditional Chinese medicines (TCMs) and adefovir (ADV) antihepatitis B virus (HBV) infection trial in the world. A total of 560 hepatitis B e antigen- (HBeAg-) positive Chinese patients with chronical HBV were randomly classified, in 1 : 1 ratio, into two groups: experimental group (EXG) receiving TCMs + ADV and controlled group (CTG) receiving ADV + TCM-placebo treatment for 48 weeks. This paper introduces two models to model and simulate the evolutions of dynamics for the complete-response patients and the poor-response patients in EXG and CTG, respectively. The stimulated mean HBV DNA and alanine aminotransferase (ALT) levels were close to the patients' experimental data. Analysis and simulations suggest that the activated patients' immune functions by TCMs + ADV may not only clear infected hepatocytes, but also clear HBV, which made the complete-response patients' mean serum HBV DNA levels in EXG reduce rapidly 12 weeks' earlier than the ones in CTG. One can assume that both the TCMs and ADV have the function of preventing complete-response patients' infected hepatocytes from being injured by cytotoxic T lymphocytes (CTLs); the patients' activated immune cells may also block HBV replications.

摘要

“ChiCTR-TRC-11001263 研究是世界上首次针对慢性乙型肝炎病毒（HBV）感染的大规模、双盲、随机、安慰剂对照的中药（TCM）和阿德福韦（ADV）抗 HBV 感染试验。共纳入 560 例 HBeAg 阳性的慢性 HBV 患者，按 1:1 比例随机分为两组：实验组（EXG）接受 TCMs+ADV 治疗，对照组（CTG）接受 ADV+TCM 安慰剂治疗 48 周。本研究分别建立了两个模型来模拟和预测 EXG 和 CTG 中完全应答患者和部分应答患者的动力学变化。模拟的 HBV DNA 和丙氨酸氨基转移酶（ALT）水平与患者的实验数据非常接近。分析和模拟结果表明，TCM+ADV 可能通过激活患者的免疫功能，不仅清除感染的肝细胞，而且清除 HBV，使 EXG 中完全应答患者的平均血清 HBV DNA 水平在 12 周前迅速下降，比 CTG 中的患者更早。可以假设 TCMs 和 ADV 都具有防止完全应答患者的感染肝细胞被细胞毒性 T 淋巴细胞（CTLs）损伤的功能；患者激活的免疫细胞也可能阻断 HBV 的复制。”

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/2c62426a73a7/ECAM2013-767290.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/cb0165708271/ECAM2013-767290.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/d1a874317399/ECAM2013-767290.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/1b091cd0fc3f/ECAM2013-767290.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/396c9a86a40a/ECAM2013-767290.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/9ec5ec4d26e8/ECAM2013-767290.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/b4199d54546a/ECAM2013-767290.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/2c62426a73a7/ECAM2013-767290.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/cb0165708271/ECAM2013-767290.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/d1a874317399/ECAM2013-767290.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/1b091cd0fc3f/ECAM2013-767290.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/396c9a86a40a/ECAM2013-767290.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/9ec5ec4d26e8/ECAM2013-767290.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/b4199d54546a/ECAM2013-767290.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af04/3825269/2c62426a73a7/ECAM2013-767290.007.jpg

相似文献

1
Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy.阿德福韦酯及中药联合阿德福韦酯治疗慢性乙型肝炎完全应答和无应答患者的动态建模与模拟。
Evid Based Complement Alternat Med. 2013;2013:767290. doi: 10.1155/2013/767290. Epub 2013 Nov 6.
2
[Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].阿德福韦酯治疗乙肝e抗原阳性慢性乙型肝炎患者三年
Zhonghua Gan Zang Bing Za Zhi. 2007 May;15(5):346-9.
3
Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial.阿德福韦酯联合中药治疗 HBeAg 阳性慢性乙型肝炎患者的随机对照 48 周研究。
Chin J Integr Med. 2020 May;26(5):330-338. doi: 10.1007/s11655-020-3250-0. Epub 2020 Jan 10.
4
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎：系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
5
[A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].国产阿德福韦酯治疗乙肝e抗原阳性慢性乙型肝炎患者的临床研究
Zhonghua Gan Zang Bing Za Zhi. 2006 Dec;14(12):898-901.
6
[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].[多种基于抗病毒治疗策略对乙肝e抗原阳性且rtN236T突变的慢性肝炎患者的临床疗效]
Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):184-8.
7
[Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].[比较替比夫定联合阿德福韦酯与拉米夫定联合阿德福韦酯对乙型肝炎病毒感染患者肾功能的影响]
Zhonghua Gan Zang Bing Za Zhi. 2018 Apr 20;26(4):288-293. doi: 10.3760/cma.j.issn.1007-3418.2018.04.011.
8
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.阿德福韦酯在中国HBeAg阳性慢性乙型肝炎患者中的双盲随机试验。
Hepatology. 2006 Jul;44(1):108-16. doi: 10.1002/hep.21225.
9
Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy.对于对阿德福韦酯（ADV）单药治疗反应欠佳的慢性乙型肝炎患者，阿德福韦酯与拉米夫定、替比夫定或恩替卡韦的优化联合疗法可能有效。
Int J Clin Exp Med. 2015 Nov 15;8(11):21062-70. eCollection 2015.
10
Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.在对拉米夫定产生临床或病毒学耐药的HBeAg阴性慢性乙型肝炎病毒感染成人患者中，比较阿德福韦与拉米夫定联合用药和阿德福韦单药治疗：一项回顾性、多中心、非随机、开放标签研究。
Clin Ther. 2008 Feb;30(2):317-23. doi: 10.1016/j.clinthera.2008.02.012.

本文引用的文献

1
Dynamics of a delay differential equation model of hepatitis B virus infection.乙型肝炎病毒感染的时滞微分方程模型的动力学。
J Biol Dyn. 2008 Apr;2(2):140-53. doi: 10.1080/17513750701769873.
2
Endpoints of hepatitis B treatment.乙型肝炎治疗的终点。
J Viral Hepat. 2010 Oct;17(10):675-84. doi: 10.1111/j.1365-2893.2010.01369.x.
3
Chronic hepatitis B: update 2009.慢性乙型肝炎：2009年更新
Hepatology. 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190.
4
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.亚太地区慢性乙型肝炎管理共识声明：2008 年更新版。
Hepatol Int. 2008 Sep;2(3):263-83. doi: 10.1007/s12072-008-9080-3. Epub 2008 May 10.
5
Rich dynamics of a hepatitis B viral infection model with logistic hepatocyte growth.具有逻辑斯蒂肝细胞生长的乙型肝炎病毒感染模型的丰富动力学
J Math Biol. 2010 Apr;60(4):573-90. doi: 10.1007/s00285-009-0278-3. Epub 2009 Jun 17.
6
The dynamics of a delay model of hepatitis B virus infection with logistic hepatocyte growth.具有逻辑斯蒂肝细胞生长的乙型肝炎病毒感染延迟模型的动力学
Math Biosci Eng. 2009 Apr;6(2):283-99. doi: 10.3934/mbe.2009.6.283.
7
On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future.慢性乙型肝炎治疗期间的治疗结果预测与调整：现状与未来。
Antivir Ther. 2009;14(1):13-22.
8
EASL Clinical Practice Guidelines: management of chronic hepatitis B.欧洲肝脏研究学会临床实践指南：慢性乙型肝炎的管理
J Hepatol. 2009 Feb;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001. Epub 2008 Oct 29.
9
Hepatitis B: reflections on the current approach to antiviral therapy.乙型肝炎：关于当前抗病毒治疗方法的思考
J Hepatol. 2008;48 Suppl 1:S2-19. doi: 10.1016/j.jhep.2008.01.011. Epub 2008 Feb 4.
10
Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?抗病毒耐药乙型肝炎病毒：我们能阻止这个“怪物”滋生吗？
J Viral Hepat. 2007 Nov;14 Suppl 1:29-36. doi: 10.1111/j.1365-2893.2007.00915.x.